BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 25, 2025
See today's BioWorld
Home
» Secarna and Denali expand CNS partnership as big pharma’s demand for antisense drugs grows
To read the full story,
subscribe
or
sign in
.
Secarna and Denali expand CNS partnership as big pharma’s demand for antisense drugs grows
Oct. 27, 2021
By
Richard Staines
Secarna Pharmaceuticals GmbH & Co. KG and Denali Therapeutics Inc. have expanded a central nervous system research partnership as the gene silencing field heats up.
BioWorld
Deals and M&A
Neurology/psychiatric